Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Simcere Pharmaceutical Group Ltd. is an innovation and R&D-driven pharmaceutical company with a mission of 'providing today's patients with medicines of the future.' It focuses on therapeutic areas with significant unmet clinical needs, including oncology, central nervous system diseases, and autoimmune diseases. Simcere has established a strong presence in China and is expanding globally, leveraging its robust R&D capabilities, manufacturing excellence, and commercial network. The company is committed to developing and delivering high-quality, innovative medicines to improve patient health and quality of life.
Serves as the central hub for strategic decision-making, corporate management, research and development leadership, and coordination of global operations.
Features state-of-the-art R&D laboratories, modern office spaces, and GMP-certified manufacturing facilities, reflecting its focus on innovation and pharmaceutical production.
Emphasizes innovation, collaboration, scientific rigor, and a patient-centric approach. Fosters a dynamic environment for research and development talent.
Central to Simcere's operations, driving its R&D pipeline, strategic partnerships, and market expansion efforts both domestically in China and internationally.
Simcere Pharmaceutical Group primarily operates in China with comprehensive R&D, manufacturing, and commercial activities. It is actively expanding its global footprint through R&D centers and business development offices in the United States (e.g., Boston, Maryland) and strategic collaborations with international partners. These global functions support drug discovery, translational research, clinical development, and licensing activities, aiming to bring innovative medicines developed in China to the world, and source global innovations for the Chinese market.
Building A1, No. 699-18 Xuanwu Avenue, Xuanwu District
Nanjing
Jiangsu
China
Address: Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China (Simcere (Shanghai) R&D Co., Ltd.)
To tap into Shanghai's rich talent pool and collaborative opportunities in biotechnology and pharmaceutical research, advancing key therapeutic programs.
Address: One Broadway, 14th Floor, Cambridge, MA 02142, USA (Simcere Innovation Inc.)
To access cutting-edge research, talent, and partnership opportunities within the leading Boston/Cambridge biotech hub, fostering global drug development initiatives.
Address: Key business districts, Beijing, China (e.g., Chaoyang District)
To manage clinical trials effectively, engage with national regulatory bodies like the NMPA, and support commercial operations in Northern China.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Simcere Pharmaceutical Group' leadership includes:
Simcere Pharmaceutical Group has been backed by several prominent investors over the years, including:
Simcere Pharmaceutical Group saw a key transition in its financial leadership over the last 12 months with the departure of its CFO and the appointment of a new CFO to steer its financial strategy.
Discover the tools Simcere Pharmaceutical Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for Simcere Pharmaceutical Group likely involve combinations of employee names. For Chinese names, pinyin (Romanized spelling) is typically used. The most common patterns are often [firstinitial][lastname]@simcere.com or [firstname].[lastname]@simcere.com.
firstinitiallastname@simcere.com
Format
jdoe@simcere.com
Example
75%
Success rate
PR Newswire • April 26, 2024
Simcere Pharmaceutical Group announced that its SOS1 inhibitor (SCR-8554) for treating advanced solid tumors has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) to initiate clinical trials....more
PR Newswire • March 27, 2024
Simcere reported its 2023 annual results, highlighting a 26.3% year-on-year increase in revenue from innovative drugs, reaching RMB 4.06 billion. Total revenue was RMB 6.11 billion, with R&D investment accounting for 27.8% of pharmaceutical revenue....more
PR Newswire • January 18, 2024
Simcere Pharmaceutical Group and Novoimmune Ltd. announced a strategic collaboration to co-develop novel bi-specific and tri-specific antibodies for cancer treatment, leveraging Novoimmune's nITAb platform and Simcere's R&D and commercialization capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Simcere Pharmaceutical Group, are just a search away.